Radiotherapy in DCIS, an underestimated benefit?

Radiotherapy and Oncology

Volumn 112, Issue 1, 2014, Pages 1-8

  Cutuli, Bruno ^a   Bernier, Jacques ^b   Poortmans, Philip ^c  

^a Institut du Cancer Courlancy   (France)

^b Genolier Swiss Medical Network SA   (Switzerland)

^c DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Ductal carcinoma in situ; Local recurrence; Prognostic factors; Radiation therapy; Surgery

Indexed keywords

TAMOXIFEN;

AGE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NUCLEAR GRADE; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TUMOR VOLUME; ADJUVANT THERAPY; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; METHODOLOGY; POSTOPERATIVE PERIOD; PROCEDURES; PROGNOSIS; SEGMENTAL MASTECTOMY; SURGERY; TREATMENT OUTCOME; TUMOR RECURRENCE;

BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84908897499     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.06.011     Document Type: Review

References (103)

1. Bleicher RJ. Duct carcinoma in situ. Surg Clin N Am 2013;93:393-410.
2. Punglia RS, Burstein HJ, Weeks JC. Treatment of duct carcinoma in situ after excision: would a prophylactic paradigm be more appropriate? J Natl Cancer Inst 2013;105:1527-33.
3. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade duct carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow up. Cancer 2005;103:2481-4.
4. Mokbel K, Cutuli B. Heterogeneity of duct carcinoma in situ and its effects on management. Lancet Oncol 2006;7:756-65.
5. Warren JL, Weaver DL, Bocklage T, et al. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS. Cancer 2005;104:1840-8.
6. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103:478-88.
7. Donker M, Litiere S, Werutski G, et al. Breast-conserving treatment with or without radiotherapy in duct carcinoma in situ: 15-year recurrence rates and outcomes after a recurrence rates and outcome after a recurrence, from EORTC 10583 randomized phase III trial. J Clin Oncol 2013;31:4054-9.
8. Cutuli B, Lemanski C, Le Blanc-Onfroy M, et al. Local recurrence after duct carcinoma in situ breast conserving treatment. Analysis of 195 cases. Cancer Radiother 2013;17:196-201.
9. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of duct carcinoma in situ. A meta-analysis. Cancer 1999;85:616-28.
10. Kricker A, Goumas C, Amstrong B. Duct carcinoma in situ of the breast. A population-based study of epidemiology and pathology. Br J Cancer 2004;90:1382-5.
11. Baxter N, Virnig BA, Durham JB, Tuttle TM. Trend in treatment of duct carcinoma in situ of the breast. J Natl Cancer Inst 2004;96:443-8.
12. Cutuli B, Lemanski C, Fourquet, et al. Breast conserving surgery with or without radiotherapy versus mastectomy for duct carcinoma in situ. French survey experience. Br J Cancer 2009;100:1048-54.
13. Sprague BL, Laughlin MC, Hampton JM, Newcomb PA, Trentham-Dietz A, Sprague BL. Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study. Breast Cancer Res Treat 2013;141:145-54.
14. Alvarado R, Lari SA, Roses RE, et al. Biology treatment and outcome in very young and older women with DCIS. Ann Surg Oncol 2012;19:3777-84.
15. Schouten van Der Velden AP, van Vugt R, van Dijck JA, Leer JW, Wobbes T. Local recurrences after different treatment strategies for duct carcinoma in situ of the breast: a population-based study in the east Netherlands. Int J Radiat Oncol Biol Phys 2007;69:703-10.
16. Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJT. Clinical outcome after selective treatment of patients diagnosed with duct carcinoma in situ of the breast. Ann Surg Oncol 2008;15:235-43.
17. Silverstein MJ. Duct carcinoma in situ of the breast: 11 reason to consider treatment with excision alone. Women's Health 2008;4:565-77.
18. Mac Donald HR, Silverstein MJ, Mabry H, et al. Local control in duct carcinoma in situ treated by excision alone; incremental benefit of larger margins. Am J Surg 2005;190:521-5.
19. Tunon de Lara C, de Mascarel I, Mac Grogan G, et al. Analysis of 676 duct carcinoma in situ [DCIS] of the breast from 1971 to 1995: diagnosis and treatment; the experience of one institute. Am J Clin Oncol 1971;2001:531-6.
20. Cutuli B, Cohen Solal Le Nir C, Cutuli B, de Lafontan B, et al. Breast conserving therapy for duct carcinoma in situ of the breast: the French Cancer centers' experience. Int J Radiat Oncol Biol Phys 2002;53:868-79.
21. Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA. Carcinoma in situ of the female breast. 10-year follow-up results of a prospective nation-wide study. Breast Cancer Res Treat 2000;62:197-210.
22. Schwartz GF. Treatment of subclinical duct carcinoma in situ of the breast by local excision and surveillance: an update personal experience. In: Silverstein MJ, Recht A, Lagios M, editors. Duct carcinoma in situ of the breast. Philadelphia: Lippincott William and Wilkins; 2002. p. 308-21.
23. Guerrieri-Gonzaga A, Botteri E, Lazzeroni, et al. Low-dose tamoxifen in the treatment of breast duct intraepithelial neoplasia: results of a large observational study. Ann Oncol 2010;21:949-54.
24. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial duct carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102:627-37.
25. Rakovitch E, Nofech-Mozes S, Narod S, et al. Can we select individuals with low risk duct carcinoma in situ [DCIS]? A population-based outcomes analysis. Breast Cancer Res Treat 2013;138:581-90.
26. Fowble B. Overview of conservative surgery and radiation therapy duct carcinoma in situ. In: Silverstein MJ, Recht A, Lagios M, editors. Duct carcinoma in situ of the breast. Philadelphia: Lippincott William and Wilkins; 2002. p. 287-302.
27. Fourquet A, Sigal-Zafrani B, Clough KB. Breast-conserving surgery plus radiation therapy in duct carcinoma in situ: the Institut Curie experience. In: Silverstein MJ, Recht A, Lagios M, editors. Duct carcinoma in situ of the breast. Philadelphia: Lippincott William and Wilkins; 2002. p. 367-72.
28. Halasz LM, Sreedhara M, Chen YH, et al. Improved outcomes of breast-conserving therapy for patients with duct carcinoma in situ. Int J Radiat Oncol Biol Phys 2012;82:e581-6.
29. Falk RS, Hofvind S, Skaane P, Haldorsen T. Second events following duct carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Res Treat 2011;129:929-38.
30. Tunon de Lara C, Andre G, Mac Grogan G, et al. Duct carcinoma in situ of the breast: influence of age on diagnostic, therapeutic and prognostic features. Retrospective study of 812 patients. Ann Surg Oncol 2011;18:1372-9.
31. Vidali C, Caffo O, Aristei C, et al. Conservative treatment of breast duct carcinoma in situ: results of an Italian multi-institutional retrospective study. Radiat Oncol 2012;7:177.
32. Shaitelman SF, Wilkinson JB, Kestin LL, et al. Long-term outcome in patients with duct carcinoma in situ treated with breast-conserving therapy: implications for optimal follow-up strategies. Int J Radiat Oncol Biol Phys 2012;83:e305-12.
33. Lagios MD. Practical pathology of duct carcinoma in situ: how to derive optimal data from the pathologic examination. In: Silverstein MJ, Recht A, Lagios M, editors. Duct carcinoma in situ of the breast. Philadelphia: Lippincott William and Wilkins; 2002. p. 207-21.
34. Silverstein MJ. The Van Nuys/USC experience by treatment. In: Silverstein MJ, Recht A, Lagios M, editors. Duct carcinoma in situ of the breast. Philadelphia: Lippincott William and Wilkins; 2002. p. 337-42.
35. Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraduct breast cancer. N Engl J Med 1993;328:1581-6.
36. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from National Surgical Adjuvant Breast Project [NSABP]. Eight-year update of protocol B-17: intraduct carcinoma. Cancer 1999;86:429-38.
37. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conservative treatment for duct carcinoma in situ: first results of the EORTC randomised phase III trial 10853. Lancet 2000;355:528-33.
38. Bijker N, Peterse JL, Duchateau L, et al. Risk factor for recurrence and metastasis after breast conserving therapy for duct carcinoma in situ: analysis of European Organisation for Research and Treatment of Cancer trial 10853. J Clin Oncol 2001;19:2263-71.
39. Bijker N, Meijnen PH, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in duct carcinoma in situ: ten-year results of European Organisation for research and treatment of cancer randomized phase III trial 10853-a-study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:3381-7.
40. Emdin S, Granstrand B, Ringberg A, et al. SweDCIS: radiotherapy after sector resection for duct carcinoma in situ of the breast. Results of a randomized trial in a population offered mammographic screening. Acta Oncol 2006;45:536-43.
41. Holmberg L, Garmo H, Grandstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for duct carcinoma in situ of the breast. J Clin Oncol 2008;26:1247-52.
42. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised duct carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
43. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised duct carcinoma in situ: long-term results of from the UK/ANZ DCIS trial. Lancet Oncol 2011;12:21-9.
44. Early Breast Cancer Trialists' Collaborative Group [EBCTCG]. Overview of the randomized trial of radiotherapy in duct carcinoma in situ of the breast. J Natl Cancer Inst Monog 2010;41:162-77.
45. Rakovitch E, Pignol JP, Chartier C, et al. The management of duct carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat 2007;3:335-47.
46. Holmberg L, Wong YNS, Tabar L, et al. Mammography casting-type calcification and risk of local recurrence in DCIS: analyses from a randomised study. Br J Cancer 2013;108:812-9.
47. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with duct carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001;28:400-18.
48. Solin LJ, Fourquet A, Vicini LJF, et al. Mammographically detected duct carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys 2001;50:991-1102.
49. Vicini FA, Shaitelman S, Wilkinson JB, et al. Long-term impact of young age at diagnosis on treatment outcome and patterns of failure in patients with duct carcinoma in situ treated with breast conserving therapy. Breast J 2013;19:365-73.
50. Meattini I, Livi L, Franceschini D, et al. Role of radiotherapy boost in women with duct carcinoma in situ: a single-center experience in a series of 389 cases. Eur J Surg Onc 2013;39:613-8.
51. Omlin A, Amichetti M, Azria D, et al. Boost radiotherapy in young women with duct carcinoma in situ: a multicentre retrospective study of the Rare Cancer Network. Lancet Oncol 2006;8:652-6.
52. Smith BD, Haffty BG, Buchnoltz TA, et al. Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst 2006;98:1302-10.
53. Solin L, Fourquet A, Vicini F, et al. Long-term outcome after breast conservation treatment with radiation for mammographically detected duct carcinoma in situ of the breast. Cancer 2005;1003:1137-46.
54. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for duct carcinoma in situ of the breast. Cancer 1996;77:2267-74.
55. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of duct carcinoma in situ of the breast. N Engl J Med 1999;340:1455-61.
56. Silverstein MJ. Margin width as the sole predictor of local recurrence in patients with duct carcinoma in situ of the breast. In: Silverstein MJ, Recht A, Lagios M, editors. Duct carcinoma in situ of the breast. Philadelphia: Lippincott William and Wilkins; 2002. p. 482-93.
57. Sigal-Zafrani B, Lewis JS, Clough KB, et al. Histological margin assessment for breast duct carcinoma in situ: precision and implication. Mod Pathol 2004;17:81-8.
58. Schwartz GF, Solin LJ, Olivotto IA, et al. Consensus conference on the treatment of in situ duct carcinoma of the breast, April 22-25, 1999. Cancer 2000;88:946-54.
59. Monteau A, Sigal-Zafrani B, Kirova Y, et al. Duct carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with re-excision or radiotherapy with increased dosage. Int J Radiat Oncol Biol Phys 2009;75:1021-8.
60. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for duct carcinoma in situ. J Clin Oncol 2009;27:1615-20.
61. Wang SY, Shamliyan T, Jalal H, Kuntz KM, Kane RL, Virnig BA. Network meta-analysis of margin threshold for women with duct carcinoma in situ. J Natl Cancer Inst 2012;104:507-16.
62. Benson JR, Wishart GC. Predictors of recurrence for duct carcinoma in situ after breast conserving surgery. Lancet Oncol 2013;14:e348-57.
63. Vicini FA, Kestin LL, Goldstein NS, et al. Relationship between excision volume, margin status and tumor size with the development of local recurrence in patients with duct carcinoma in situ treated with breast-conserving therapy. J Surg Oncol 2001;76:245-54.
64. Allred DC. Duct carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monog 2010;2010:134-8.
65. Soeteman DI, Stout NK, Ozanne EM, et al. Modelling the effectiveness of initial management strategies for duct carcinoma in situ. J Natl Cancer Inst 2013;105:774-81.
66. Yi M, Meric-Bernstam F, Kuerer HM, et al. Evaluation of a breast cancer mamogram for predicting risk of ipsilateral breast tumor recurrences in patients with duct carcinoma in situ after local excision. J Clin Oncol 2012;30:600-7.
67. van Zee KJ, Liberman L, Samli B, et al. Long-term follow-up of women with duct carcinoma in situ treated with breast conserving surgery. The effect of age. Cancer 1999;86:1757-67.
68. Rudloff U, Jacks LM, Goldberg JL, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for duct carcinoma in situ. J Clin Oncol 2010;28:3762-9.
69. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer 2011;2:232-61.
70. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 2011;104:120-7.
71. Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridization of duct carcinoma in situ of the breast; evidence of multiple genetic pathways. J Pathol 1999;187:396-402.
72. Hannemann J, Velds A, Halfwerk, Kreike B, Peterse JL, VanDeVijver MJ. Classification of duct carcinoma in sity by gene expression profiling. Breast Cancer Res 2006;8:R61.
73. Balleine RL, Webster LR, Davis S, et al. Molecular grading of duct carcinoma in situ of the breast. Clin Cancer Res 2008;14:8244-52.
74. Wulfkuhle JD, Sgroi DC, Krutzsch H, et al. Proteomics of human breast duct carcinoma in situ. Cancer Res 2002;62:6740-9.
75. Gotte M, Kersting C, Radke I, Kiesel L, Wuffling P. An expression signature of syndecan 1 [CD 138], E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in duct breast carcinoma in situ. Breast Cancer Res 2007;9:R6.
76. Gonzalez LO, Junquera S, del Casar JM, et al. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and miwed invasive and in situ duct carcinomas of the breast. Hum Pathol 2010;41:980-9.
77. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for duct carcinoma in situ of the breast. J Natl Cancer Inst 2013;105:701-10.
78. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versuis no boost. EORTC 22881-10882 trial. J Clin Oncol 2007;25:3259-65.
79. Rakovitch E, Narod SA, Nofech-Moses S, et al. Impact of boost radiation in the treatment of ductal carcinoma in situ: a population-based analysis. Int J Rad Oncol Biol Phys 2013;86:491-7.
80. Meattini I, Livi L, Franceschini D, et al. Role of radiotherapy boost in women with ductal carcinoma in situ: a single-center experience in a series of 389 cases. Eur J Surg Onc 2013;39:613-8.
81. Petrelli F, Bardni S. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. Radiother Oncol 2011;100:195-9.
82. Wallis MG, Clements K, Kearins O, et al. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 2012;106:1611-7.
83. Pinsky RW, Rebner M, Pierce LJ, et al. Recurrent cancer after breast-conserving surgery with radiation therapy for duct carcinoma in situ: mammographic features, method of detections, and stage of recurrence. Am J Roentgenol 2007;1889:140-4.
84. Romero L, Klein L, Ye W, et al. Outcome after invasive recurrence in patients with duct carcinoma in situ of the breast. Ann J Surg 2004;188:371-6.
85. Solin L, Fourquet A, Vicini F, et al. Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for duct carcinoma in situ. Eur J Cancer 2005;41:1715-23.
86. Ceilley E, Jagsi R, Goldberg S, Powell S, Taghian A. The management of ductal carcinoma in situ in North America and Europe. Results of a survey. Cancer 2004;101:1958-67.
87. Vicini F, Shah C, Wilkinson JB, Keish M, Beitch P, Lyden M. Should ductal carcinoma in situ [DCIS] be removed from the ASTRO consensus panel cautionary for off-protocol use of accelerated partial breast irradiation [APBI]? A pooled analysis of outcomes for 300 patients, with DCIS treated with APBI. Ann Surg Oncol 2013;20:1275-81.
88. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for duct carcinoma in situ of the breast. Cochrane Database Syst Rev 2013;11:CD000563. http://dx.doi.org/10.1002/14651858.
89. Lagios MD, Silverstein MJ. Duct carcinoma in situ: the success of breast conservation therapy: a shared experience of two single institutional nonrandomized prospective studies. Surg Oncol Clin N Am 1997;6:383-92.
90. Smith GL, Smith BD, Haffty BG. Rationalization and regionalization of treatment for duct carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 2006;5:1397-403.
91. Wong J, Chen YH, Gadd MA, et al. Eight-year update of a prospective study of wide excision alone for small, low- or intermediate-grade ductal carcinoma in situ [DCIS]. Breast Cancer Res Treat 2014;143:343-50.
92. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for duct carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:5319-24.
93. Motwani SB, Goyal S, Moran MS, Chhabra A, Haffty BG. Duct carcinoma in situ treated with breast-conserving surgery and radiotherapy: a comparison with ECOG study 5194. Cancer 2011;117:1156-62.
94. Rakovitch E, Narod SA, Nofech-Moses S, et al. Impact of boost radiaton in the treatment of ductal carcinoma in situ: a population-based analysis. Int J Radiat Oncol Biol Phys 2013;86:491-7.
95. Wong P, Lambert C, Agnihotram RV, David M, Duclos M, Freeman CR. Ductal carcinoma in situ. The influence of the radiotherapy boost on local control. Int J Radiat Oncol Biol Phys 2012;82:e153-8.
96. Park CK, Li X, Starr J, Harris EE. Cardiac morbidity and mortality in women with duct carcinoma in situ of the breast treated with breast conservation therapy. Breast J 2011;17:470-6.
97. Marhin W, Wai E, Tyldesley S. Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer. Int J Radiat Oncol Biol Phys 2007;69:483-9.
98. Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005;97:419-24.
99. Grantzau T, Mellemkjaer L, Overgaard J. Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population-based study under the Danish Breast Cancer Cooperative Group [DBCG]. Radiother Oncol 2013;106:42-9.
100. Boxer MM, Delaney GP, Chua BH. A review of the management of duct carcinoma in situ following breast conserving surgery. The Breast 2013;22:1019-25.
101. Riou O, Lemanski C, Guillaumon V, et al. Role of the radiotherapy boost on local control in duct carcinoma in situ. Int J Surg Oncol 2012;2012:748196. http://dx.doi.org/10.1155/2012/748196.
102. Allred DC, Wu Y, Mao S., et al., Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008;14:370-8.
103. Soumian S, Verghese ET, Booth M, et al. Concordance between vacuum assisted biopsy and postoperative histology implications for the proposed low-risk DCIS trial [LORIS]. Eur J Surg Oncol 2013;39:1337-40.